Malaria parasites replicate within a parasitophorous vacuole in red blood cells (RBCs). Progeny merozoites egress upon rupture of first the parasitophorous vacuole membrane (PVM), then poration and rupture of the RBC membrane (RBCM). Egress is protease-dependent
1 , but none of the effector molecules that mediate membrane rupture have been identified and it is unknown how sequential rupture of the two membranes is controlled. Minutes before egress, the parasite serine protease SUB1 is discharged into the parasitophorous vacuole [2] [3] [4] [5] [6] where it cleaves multiple substrates 2,5,7-9 including SERA6, a putative cysteine protease [10] [11] [12] . Here, we show that Plasmodium falciparum parasites lacking SUB1 undergo none of the morphological transformations that precede egress and fail to rupture the PVM. In contrast, PVM rupture and RBCM poration occur normally in SERA6-null parasites but RBCM rupture does not occur. Complementation studies show that SERA6 is an enzyme that requires processing by SUB1 to function. RBCM rupture is associated with SERA6-dependent proteolytic cleavage within the actin-binding domain of the major RBC cytoskeletal protein β -spectrin. We conclude that SUB1 and SERA6 play distinct, essential roles in a coordinated proteolytic cascade that enables sequential rupture of the two bounding membranes and culminates in RBCM disruption through rapid, precise, SERA6-mediated disassembly of the RBC cytoskeleton.
Malaria, caused by parasitic protozoa of the genus Plasmodium, causes over 400,000 deaths per annum. With widespread resistance to most antimalarial drugs, there is a need to better understand the biology of the parasite, especially the species responsible for most fatalities, Plasmodium falciparum. Asexual blood stage parasites proliferate within RBCs. Following each cycle of intracellular development (lasting ~48 h in P. falciparum) the PVM and RBCM rupture to allow egress of merozoites, which invade fresh RBCs.
Egress comprises several rapidly successive steps. Following biogenesis of intracellular merozoites by segmentation of the mature schizont, the PVM becomes permeable, allowing mixing of the contents of the parasitophorous vacuole and residual RBC cytoplasm 6 . Within the ensuing minutes, the parasite cGMP-dependent protein kinase PKG is activated to trigger discharge of SUB1, a subtilisin-like protease, from merozoite secretory organelles called exonemes 3, 4 . In the lumen of the parasitophorous vacuole, SUB1 proteolytically modifies several merozoite surface and parasitophorous vacuole proteins 2, 5, 7, 8 , including SERA6, which is cleaved to release a central domain with homology to papain-like (clan CA, family C1) cysteine peptidases 10 . Within ~10 min of SUB1 discharge, the parasitophorous vacuole abruptly swells while the entire infected RBC transforms from an irregular to a roughly spherical 'flower' or rounded-up structure 13, 14 . The PVM then fragments into multilamellar vesicles, closely followed by collapse and poration (permeabilization) of the RBCM 6, 14, 15 . Within seconds the RBCM ruptures, allowing merozoite release 16 . Inhibitors of PKG block SUB1 discharge and all stages of egress subsequent to the initial PVM permeabilization step 3, 5, 6, 17 . In contrast, the broad-spectrum cysteine protease inhibitor epoxysuccinyl-L-leucylamido(4-guanidino)butane (E64), which does not inhibit SUB1 activity 3 , prevents neither PVM rupture nor RBCM collapse and poration, but blocks the final step of RBCM rupture 6, 14, 15, 18 . We used the rapamycin (RAP)-inducible dimerizable Cre recombinase (DiCre) system 19, 20 to conditionally excise either a segment of the SUB1 gene encoding crucial catalytic residues, or the entire SERA6 coding sequence (Fig. 1a) . In each case, PCR (Fig. 1a ) and western blot ( Fig. 1b and Supplementary Fig. 1 ) demonstrated rapid and efficient RAP-induced excision of the floxed DNA sequences and ablation of SUB1 or SERA6 expression. Immunofluorescence analysis (IFA) confirmed loss of SUB1 in 99.8% of schizonts (of 5,056 examined) by the end of the erythrocytic cycle (cycle 0) in which the parasites were treated with RAP (Fig. 1c) . Both SUB1-null (ΔSUB1) and ΔSERA6 parasites formed morphologically normal schizonts at the end of cycle 0, showing that neither gene is required for intracellular development (Fig. 1c) . However, over the ensuing erythrocytic cycles there was a dramatic reduction in replication rates of the RAP-treated cultures (Fig. 1d) . Monitoring over 8-10 erythrocytic cycles showed that the initially minor population of non-excised parasites gradually overgrew these cultures while the ΔSUB1 or ΔSERA6 parasites disappeared (Fig. 1e) , indicating a severe defect. To further assess the impact of gene disruption we used a plaque assay 12 that captures successive rounds of replication by individual parasite clones. Substantial reductions in plaque numbers 
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were observed in RAP-treated cultures (Fig. 1f and ref. 12) , and the few plaques generated were found to arise from the small population of non-excised parasites ( Supplementary Fig. 2 and ref. 12 ). These results suggested that both the SUB1 and SERA6 genes are required for in vitro parasite growth.
To confirm that loss of viability was a consequence of gene disruption, plasmids for episomal expression of wild-type (WT) SUB1 or SERA6 transgenes were introduced into the (non-RAP-treated) SUB1HA3:loxP or SERA6:loxP parasites, respectively. The resulting lines were RAP-treated to disrupt the chromosomal genes, then immediately analysed by plaque assay in comparison with RAP-treated control lines harbouring 'empty' plasmids. As shown in Fig. 1f , lines carrying episomal WT SUB1 or SERA6 transgenes produced significantly more plaques following disruption of the chromosomal genes than similarly treated parasites harbouring empty plasmid. Parasites expanded from plaques produced by RAPtreated parasites carrying the episomal SUB1 or SERA6 transgenes had lost the respective chromosomal gene as expected and so were probably relying solely on the episomal gene copies ( Supplementary  Fig. 3) . Crucially, the ΔSERA6 growth defect could not be rescued by a mutant SERA6 transgene possessing an Ala substitution of the predicted catalytic Cys644 codon (expected to ablate enzyme activity 10 ) (Fig. 1f) . Similarly, the ΔSERA6 defect was not complemented by a SERA6 mutant in which the SUB1 processing sites flanking the papain-like domain were modified by Leu substitutions of the P1 and P2 residues upstream of each scissile bond; these mutations prevent SUB1-mediated cleavage 10 ( Fig. 1f) . Collectively, these findings confirmed that SUB1 and SERA6 are indispensable and indicated that SERA6 is an enzyme that requires proteolytic processing by SUB1 to perform its function.
To examine egress of ΔSUB1 and ΔSERA6 parasites, mature schizonts were incubated with the PKG inhibitor (4-
pyrimidin-2-amine (compound 2; C2), which reversibly blocks development just before egress, resulting in accumulation of 'stalled' segmented schizonts. Wash-out of the inhibitor allows rapid progress to rupture, enabling live microscopic examination of multiple egress events over the ensuing ~10-30 min 3, 5, 9 . As shown in Fig. 2a and Supplementary Video 1, ΔSUB1 parasites underwent none of the morphological changes associated with egress, with no signs of PVM swelling, rounding up, apparent PVM rupture (as indicated by loss of differential interference contrast and increased mobility of the intracellular merozoites) or RBCM rupture. Indeed, the ΔSUB1 phenotype was indistinguishable from that produced by continued incubation with C2, suggesting that SUB1 is required for all the egress-related transformations that follow PKG activation. This egress defect was completely rescued by the WT SUB1 transgene (Supplementary Video 2). As expected, proteolytic processing of the SUB1 substrates SERA5 2 , SERA6 and merozoite surface protein-1 (MSP1) 5, 7 was ablated in the ΔSUB1 parasites (Fig. 2b) . However, IFA using antibodies to AMA1, a protein released onto the merozoite surface from micronemes (which are distinct from the exonemes in which SUB1 is stored 2, 3 ) showed that microneme discharge occurred in the trapped ΔSUB1 merozoites (Fig. 2c) . Similar to SUB1 discharge, AMA1 discharge is blocked by PKG inhibitors , shaking enhanced increases in parasitaemia in mock-treated SUB1HA3:loxP cultures (Fig. 2d) , probably due to more efficient merozoite dissemination and RBC invasion. However, shaking had no impact on the low proliferation rate of RAP-treated (ΔSUB1) parasites, indicating that SUB1 is essential for release of invasive merozoites.
In contrast to the ΔSUB1 phenotype, ΔSERA6 schizonts displayed normal rounding up as well as the increases in merozoite visibility and mobility thought to indicate PVM rupture; however, RBCM rupture did not occur ( Fig. 2e and Supplementary Video 3) . Introduction of the complementing WT SERA6 expression plasmid restored egress (Supplementary Video 4) . IFA confirmed microneme discharge in the ΔSERA6 schizonts (Fig. 2f) while western blot revealed normal SUB1 activity (Fig. 2g) . Similar to the ΔSUB1 parasites, shaking did not enhance the replicative capacity of ΔSERA6 parasites (Fig. 2h) .
Upon PVM lysis, but just before RBCM rupture, the RBCM suddenly becomes permeable to the F-actin binding peptide phalloidin 9, 14, 22 . To definitively establish the fate of the PVM in the mutants and to examine the timing and efficiency of RBCM poration, SUB1HA3:loxP and SERA6:loxP parasites were transfected before RAP-treatment with a plasmid for constitutive expression of the PVM protein EXP1 23 fused to mCherry, fluorescently labelling the PVM ( Supplementary Fig. 4 ). Simultaneous differential interference contrast (DIC) and fluorescence video microscopy in the presence of fluorescent wheat germ agglutinin (which labels the RBCM surface) and fluorescent phalloidin confirmed that neither PVM rupture nor RBCM poration took place in ΔSUB1 parasites ( Fig. 3a and Supplementary Video 5). In contrast, RBCM poration occurred normally in the ΔSERA6 parasites upon PVM rupture. Examination of the arrested ΔSUB1 parasites by transmission electron microscopy (TEM) confirmed an intact PVM and RBCM indistinguishable from C2-arrested schizonts ( Fig. 3b and Supplementary Fig. 5 ). In contrast, scanning electron microscopy ( Fig. 3c) and TEM ( Fig. 3d and Supplementary Fig. 5 ) of arrested ΔSERA6 parasites revealed merozoites and PVM fragments within an intact but collapsed and evacuated RBCM, as previously observed in WT parasites arrested by E64 6 . Our observation that egress proceeded normally in the ΔSERA6 parasites up to the point of RBCM rupture suggested that SERA6 mediates RBCM breakdown. To test this model and further dissect the ΔSERA6 defect, we performed a proteomic comparison of mock-and RAP-treated SERA6:loxP schizonts. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 4a ) detected a highmolecular-mass species that appeared within 20 min in soluble fractions of mock-treated parasites allowed to undergo egress, identified as a truncated form of β -spectrin, a major RBC cytoskeleton protein. Further quantitative tandem mass spectrometry (LC-MS/ MS) analysis revealed the concomitant appearance of one or more lower molecular mass polypeptides comprising the N-terminal calponin homology (CH) domain of the β -spectrin actin-binding domain (ABD) ( Fig. 4b and Supplementary Fig. 6 ). This suggested that RBCM rupture is associated with proteolytic cleavage of β -spectrin near its N terminus and release of the cleavage products from the cytoskeleton (which is generally insoluble in aqueous buffers). Western blot (Fig. 4c ) and pull-downs using spectrin-specific monoclonal antibodies (mAbs) combined with LC-MS/MS ( Fig. 4d and Supplementary Fig. 7 ) confirmed and extended this, showing that RBCM rupture is accompanied by extensive SERA6-dependent cleavage of β -spectrin at two closely spaced sites (Gln167-Glu168 and Gln165-Thr166) between the CH1 and CH2 domains of the ABD, releasing the CH1 domain as an ~17 kDa fragment and resulting in solubilization of the truncated β -spectrin along with some α -spectrin. The released CH1 domain copurified with human β -actin, probably also derived from the RBC cytoskeleton ( Fig. 4d and Supplementary Fig. 8 ). No proteolytic cleavage of the other major RBC cytoskeletal components α -spectrin and protein 4.1R was detectable, although limited SERA6-dependent cleavage of ankyrin was evident ( Supplementary Fig. 9 ). Strikingly, β -spectrin cleavage was never observed in ΔSERA6 parasites, even upon mechanical, hypotonic, freeze-thaw or detergent-mediated rupture of the schizonts (Fig. 4e) , showing that cleavage was not due S h a k i n g S t a t i o n a r y S t a r t S h a k i n g S t a t i o n a r y S t a r t -RAP +RAP S h a k i n g S t a t i o n a r y S t a r t S h a k i n g S t a t i o n a r y S t a r t 
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to lysis per se and implicating SERA6 as the enzyme responsible. The β -spectrin CH1 domain mediates key interactions between each end of the α 2 β 2 -spectrin tetramers that constitute the bulk of the cytoskeleton, and short β -actin filaments (together with protein 4.1 R) at the junctional complexes that link the RBC cytoskeleton to its plasma membrane, providing the latter with structural integrity (Fig. 4f ) [24] [25] [26] . Cleavage is therefore predicted to unravel the cytoskeleton with resulting RBCM destablization (Fig. 4g) . Spectrin tetramers also bind the plasma membrane through interactions with the ankyrin complex 24 , so the limited cleavage of ankyrin might facilitate release of the cleavage products and associated proteins from the cytoskeletal complex.
Our findings ascribe the physico-mechanical processes underlying malarial egress to two parasite proteases that act rapidly and sequentially within the same, PKG-regulated pathway. SUB1 is required for all the structural changes following PKG activation, including rounding up, PVM lysis, RBCM poration and RBCM rupture. SERA6 is not required for PVM rupture or RBCM poration, but accomplishes the final step of RBCM rupture primarily through targeted cleavage of β -spectrin at a site that is essential for cytoskeletal stability. PVM rupture is unlikely to be directly mediated by protease activity, so SUB1 may regulate this by activating one or more membrane lytic effectors that mediate PVM rupture, as well as perhaps RBCM poration. These could include pore-forming proteins or phospholipases, both implicated in egress of other parasite developmental stages 22, 27, 28 . That SERA6 function requires SUB1-mediated processing is consistent with processing representing activation of SERA6, as previously suggested 10 . The striking similarity between the ΔSERA6 phenotype and that produced by treatment with E64 6, 14, 18 supports this and suggests that SERA6 is the major target of E64 in schizonts. Importantly, our study proves that host RBC calpain-1, previously implicated by others in egress 29 , Fig. 6 shows fragmentation spectra). Calculated mass of the β -spectrin sequence (UniProtKB P11277) from Thr2-Gln167 is 19,251 Da. CH1, CH2, calponin homology domains. c, Appearance of an ~17 kDa N-terminal fragment of β -spectrin (arrowed) upon egress of mock-treated SERA6:loxP schizonts (reproducible in four independent experiments). d, Pull-down of cytoskeletal components from soluble extracts of egressing SERA6:loxP schizonts. Annotated species, including coprecipitating β -actin, were identified by LC-MS/MS or western blot (reproducible in three independent experiments). Peptide fingerprinting of the ~17 kDa β -spectrin CH1 domain was as in b. The presence of α -spectrin and full-length and truncated β -spectrin in pull-downs from the − RAP extracts indicates their SERA6-dependent dissociation from the normally insoluble cytoskeleton. Asterisks indicate antibody heavy and light chains. e, Fate of β -spectrin in SERA6:loxP schizonts following washing away a C2 block (control) or with additional treatment by the indicated disruption methods. Cleavage never occurred in the absence of SERA6 (western blot representative of two independent experiments). f, Architecture of RBC cytoskeleton spectrin heterotetramer, comprising two antiparallel α β -spectrin heterodimers linked head-to-head (the right-hand dimer is abbreviated for clarity), which cross-link β -actin-containing junctional complexes 24 . Spectrin repeat domains are numbered. Other structural features and positions of epitopes recognized by mAbs B-1, B-2 and VD4 are indicated. g, Top, SERA6-dependent cleavage of β -spectrin should release each end of the α β -spectrin tetramer from its cognate junctional complex. The cleaved CH1 domain may be released with actin still bound. Bottom, predicted global effect of SERA6-dependent cleavage on the cytoskeleton.
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is not sufficient for RBCM rupture since its expression should be unmodified in ΔSERA6 parasites.
All Plasmodium species, including the other major pathogens Plasmodium vivax and Plasmodium knowlesi, express orthologues of SUB1 and SERA6. Drugs that inhibit these proteases, particularly if combined with inhibitors of PKG 30 , would target consecutive, interdependent steps in the egress pathway and so could form a new class of antimalarial designed to prevent parasite proliferation and disease.
Methods
Reagents and antibodies. Anonymised human blood was obtained from the UK National Blood Transfusion Service. The antifolate WR99210 was from Jacobus Pharmaceuticals. Blasticidin, RAP and E64 (Sigma) were used as described previously 9, 19 . Compound 2 was kindly provided by S. Osborne (LifeArc); stocks (10 mM) were stored in DMSO at − 20 °C and used throughout at a final concentration of 1 μ M. Alexa Fluor 488 phalloidin and Alexa Fluor 647-conjugated WGA were from ThermoFisher. The β -spectrin-specific mAbs B-1, B-2 and VD4, the α -spectrin-specific mAb 17C7, and mAbs B-11 and 8C3 specific for protein 4.1 R and ankyrin, respectively, were all from Santa Cruz Biotechnology. Monoclonal antibody 7.7 (anti-EXP2) was from the European Malaria Reagent Repository (http://www.malariaresearch.eu/), contributed by Jana McBride. The polyclonal anti-mCherry antibody (ab167453) was from Abcam. The P. falciparum MSP1-specific mAb 89.1 has been described previously 31 , as have rabbit antisera to P. falciparum SERA5 9 , SERA6 10 , SUB1 32 and AMA1
33
. Phusion high-fidelity DNA polymerase and restriction enzymes were from New England BioLabs, and a Rapid DNA Ligation Kit (Roche) was used for DNA ligation.
Parasite maintenance, synchronization and transfection. The DiCre-expressing P. falciparum clone 1G5DC 19 was maintained at 37 °C in human RBCs in RPMI 1640 medium containing Albumax (Invitrogen) supplemented with 2 mM L-glutamine. Cultures were routinely monitored by microscopic examination of Giemsa-stained thin blood films and synchronized by standard procedures 34 . As required, mature schizonts were isolated by centrifugation over cushions of 70% (v/v) isotonic Percoll (GE Healthcare Life Sciences) as described in a published study 34 . Invasion assays were performed as previously described 3, 5 , either in static culture or in a shaking incubator revolving at 225 r.p.m. For transfection of plasmid constructs, ~10 8 Percoll-enriched schizonts were suspended in 100 μ l of P3 primary cell solution containing 10 μ g of DNA and electroporated with an Amaxa P3 primary cell 4D Nucleofector X Kit L (Lonza), using program FP158 as previously described 5 . Growth medium was supplemented ~20 h post transfection with WR99210 (2.5 nM) or blasticidin (2 μ g ml -1 ). Once sustained growth of drugresistant parasites was observed, drug cycling was used to enrich for genomic integration of plasmid constructs as previously described 2 . Transgenic parasite clones SUB1HA3:loxP and SERA6:loxP were obtained by limiting dilution cloning in microplates at 0.1-0.3 parasites per well. Parasite genomic DNA (gDNA) for genotype analysis was extracted using a Qiagen DNeasy Bood and Tissue kit and analysed by PCR using Kappa 2 G Fast HotStart ReadyMix (Kappa Biosciences).
Immunofluorescence and western blot. For IFA, air-dried thin films of parasite cultures were fixed in paraformaldehyde, permeabilized, then probed with relevant primary antibodies as described previously 10 . Secondary Alexa Fluor 488-or 594-conjugated antibodies specific for human, rabbit or mouse IgG (Invitrogen), or Alexa Fluor 594-conjugated streptavidin (Invitrogen) were used at a dilution of 1:1,000. Samples were mounted in Vectashield antifade mounting medium (Vector Laboratories) containing 4,6-diamidino-2-phenylindole. Images were acquired using a Nikon Eclipse and NIS-Elements software (Nikon, Japan), using identical exposure conditions for all samples being compared. Western blots were performed as described previously 33 . For detection of HA3-tagged SUB1, the rat anti-HA mAb 3F10 (Sigma) was used at a 1:1,000 dilution, followed by biotin-conjugated antirat antibody (Roche) (1:8,000 dilution), then horseradish peroxidase-conjugated streptavidin (Sigma) (1:10,000 dilution). Immobilon Western Chemiluminescent HRP Substrate (Millipore) was used according to the manufacturer's instructions, and blots were visualized and documented using a ChemiDoc Imager (Bio-Rad) with Image Lab software (Bio-Rad).
Generation of integration, complementation and expression plasmids.
SUB1HA3:loxP and SERA6:loxP parasite clones were generated by single crossover homologous recombination into the 1G5DC genome using integration plasmids pHH1_SUB1HA3_loxP and pHH1_S6chimera_loxP, respectively. In both cases, correct transcriptional regulation of the modified gene was assured by placement of the 3' untranslated region (UTR) of the Plasmodium berghei dihydrofolate reductase thymidylate synthase (PbDT) gene downstream of the floxed coding sequence 19 . To target the SUB1 gene, a chimeric gene fragment with a native 5' portion and a recodonized 3' segment was constructed by first amplifying the 5' sequence from P. falciparum 3D7 gDNA using primers JT-S1endo-F and JT-S1CO-R, while the recodonized region was amplified from plasmid pFastBacsPfSUB1wt 32 using primers JT-S1CO-F and JT-S1synth-R. The amplicons were then fused in frame by inclusion of both in a fresh PCR reaction including primers JT-S1endo-F and JT-S1synth-R, and the product cloned into pGEM-T (Promega). A segment of this fragment was then excised using HindIII and KpnI and replaced with a similarly digested loxP-containing synthetic intron (loxPint) 20 (Geneart). This intermediate vector was digested with HpaI and XhoI to liberate the SUB1 sequence, which was ligated into pHH1_sera5_LoxP1 19 digested with the same enzymes to generate pHH1_SUB1HA3_loxP. Integration of this construct into the 1G5DC SUB1 locus by homologous recombination was detected by diagnostic PCR with primers JT111-1p and JT111-2p, and the floxed or excised SUB1 locus was detected by PCR using primers JT111-1p and JT111-3p.
To generate pHH1_S6chimera_loxP, a chimeric SERA6 gene fragment was excised from plasmid MWS36 by digestion with HpaI and NcoI. Full details of plasmid MWS36 will be provided in a separate manuscript (M. Shea and M. Blackman, manuscript in preparation). The chimeric SERA6 sequence comprised a 920 bp 5' portion of endogenous coding sequence starting from within the first intron followed by synthetic recodonized SERA6 cDNA sequence extending to the stop codon. Plasmid pHH1_sera5_LoxP1 was digested with HindIII, 'blunted' with T4 DNA polymerase, then further digested with NcoI before ligation to the chimeric SERA6 fragment excised from MWS36, generating pHH1_S6chimera_ loxP. Integration of this construct by homologous recombination into the 1G5DC genome (which already contains a single genomic loxP site upstream of the SERA6 locus 19 ) was designed to introduce a second loxP site downstream of the SERA6 stop codon. Correct integration was detected by diagnostic PCR using primers SERA6-5'UTRb and SERA6-37, while the floxed or excised SERA6 locus was detected with primers S65'UTRb-2 and S6EndoEx2Rev.
For generation of plasmid constructs designed for transgenic expression of SERA6, a chimeric coding sequence and native SERA6 promoter was excised from plasmid MW28 and ligated into SalI and NcoI digested plasmid pDC-mCherry-MCS (a modification of pDC2-mCherry 9 ), giving rise to pDC2-wtSERA6 (WT SERA6). The chimeric SERA6 sequence comprised 979 bp of putative promoter sequence upstream of the native SERA6 ATG start codon, as well as 477 bp of the 5' segment of the coding sequence (including the first intron) and a synthetic recodonized SERA6 cDNA 10 encoding the remainder of the open reading frame (ORF). Full details of plasmid MWS28 will be provided in a separate manuscript (M. Shea and M. Blackman, manuscript in preparation). Site-directed mutagenesis and subcloning steps were then used as previously described 10 to generate identical constructs containing di-Leu substitutions of the P1 and P2 positions at the SUB1 processing sites 1 and 2 in SERA6, as well as a Cys644Ala substitution of the active site nucleophile, giving rise to plasmids pDC2-SERA6-uncleavable (uncleavable SERA6) and pDC2-SERA6_Alamut (Cys644Ala), respectively.
For transgenic expression of WT SUB1 the pDC-mCherry-MCS plasmid was modified such that the blasticidin deaminase (BSD) drug selection cassette and mCherry reporter gene were expressed from a single promoter by the use of the ribosomal T2A skip peptide. To do this, the BSD cassette was excised from pDC2-mCherry_MCS with ApaI and SacI and the backbone re-ligated. The mCherry ORF was then excised by digestion with AvrII and XhoI and replaced with a synthetic gBlock (IDT) comprising the mCherry and BSD ORFs separated by the T2A sequence. This resulted in construct pDC2-mCherryT2ABSD_MCS in which these ORFs remained under control of the constitutive P. falciparum calmodulin (CAM) promoter (which remained from the original mCherry expression cassette). This vector was then linearized with SnaBI. The P. falciparum SUB1 promoter sequence was amplified from P. falciparum 3D7 gDNA using primers PfSUB1_prom_for_infu and PfSUB1_prom_rev_infu. Primers PfSUB1_ synth_for_infu and PfSUB1_synth_rev_infu were used to amplify the recodonized synthetic SUB1 ORF from pFastBac-sPfSUB1wt and primers PbDT3UTR-for_infu and PbDT3UTR-for_infu were used to amplify the PbDT 3' UTR from pDC2-mCherry_MCS. Primers included complementary overhangs such that all three fragments could then be finally assembled into the linearized pDC2-mCherryT2ABSD_MCS backbone in a single step using an InFusion HD Cloning Kit (Clontech), generating pDC2-mCherryT2ABSD_wtSUB1 (WT SUB1).
For episomal transgenic expression of an EXP1mCherry fusion protein (to fluorescently label the PVM), a synthetic intronless DNA fragment encoding mCherry fused to the C terminus of the P. falciparum EXP1 (PlasmoDB ID PF3D7_1121600) via a polyglycine-alanine linker (GAGGGGGGGGA) was obtained from Geneart. This was subcloned into vector pCR-Blunt using the ZeroBlunt PCR cloning kit (Invitrogen). The resulting plasmid was digested with AvrII and XhoI before ligating the EXP1mCherry fragment into pDC-mCherry-MCS in the place of the mCherry ORF, generating pDC2-EXP1-mCherry.
Parasitaemia quantitation by flow cytometry. Parasites were fixed in 4% paraformaldehyde, 0.02% glutaraldehyde for 30 min at 37 °C, diluted fivefold in phosphate-buffered saline, then stored at 4 °C until required. Cells were stained with Hoechst 33342 (diluted 1:10,000) for 30 min at 37 °C, then parasitaemia determined using a LRSFortessa or FACS Aria (BD) flow cytometer as previously described 9 . Briefly, samples were initially screened using forward and side scatter parameters and gated for RBCs (Supplementary Fig. 10 ). Ultraviolet light with a violet filter (450/50 nm) was then used to determine the proportion of infected cells in 100,000 RBCs.
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Time-lapse DIC and fluorescence video microscopy. Viewing chambers for live microscopy were constructed as described previously 3, 5 by adhering 22 × 64 mm borosilicate glass coverslips to microscope slides. Mature Percoll-enriched schizonts were incubated for 3-4 h at 37 °C in complete medium supplemented with C2 (1 μ M), then ~5 × 10 7 schizonts were rapidly washed twice in gassed, warm, complete medium lacking C2, pelleting at 1,800 × g for 1 min. The cells were suspended in 50 μ l of the same medium and introduced into the prewarmed viewing chamber on a temperature-controlled microscope stage held at 37 °C on a Nikon Eclipse Ni-E wide-field microscope fitted with a Hamamatsu C11440 digital camera and Nikon N Plan Apo λ × 100/1.45NA oil immersion objective. Images (DIC alone or simultaneous DIC and fluorescence) were taken at 5-10 s intervals over a total of 20-60 min, then annotated and exported as TIFFs, AVI or QuickTime Videos using Nikon NIS-Elements software.
Parasite plaque assays. Plaque assays were performed by dispensing parasite cultures (200 μ l at a haematocrit of 0.75%) into flat-bottomed 96-well microplates, as described 12 . Plates were imaged 14-16 days later to detect plaque formation, using an Epson Perfection V750 Pro high-resolution flat-bed scanner in top-down transmission light mode. When required, parasites from wells containing a single plaque were expanded by transferring initially to round-bottomed microplate wells to aid medium changes, before further expansion into culture flasks.
Scanning electron microscopy. Mature arrested ΔSERA6 schizonts, or WT control schizonts allowed to reach the point of egress in the presence of E64 (50 μ M) were fixed in 2.5% glutaraldehyde, washed, osmicated (1% OsO4 for 16 h), dehydrated, critical point dried and sputter coated with 5 nm gold for scanning electron microscopy. Images were collected on a JEOL JSM 7610 F with 2.6 kV accelerating voltage.
Transmission electron microscopy. Mature schizonts were fixed for 5 min at 37 °C in 2% formaldehyde (ΔSERA6 and E64-arrested schizonts) or 2% formaldehyde 1% glutaraldehyde (ΔSUB1 and C2-arrested WT schizonts), pelleted by centrifugation, mixed with 20% (w/v) dextran in complete medium containing bakers' yeast, then frozen using a HPM100 high-pressure freezer (Leica). Vitrified cells were freeze-substituted using an EM AFS2 (Leica) into Lowicryl HM20 resin (EMS) with 0.2% (w/v) uranyl acetate and cut into 250 nm or 120 nm sections using a UC7 microtome (Leica). Sections were placed on glow-discharged carbon-coated copper London Finder grids (EMS) with 10 nm Protein A-Au fiducials (EMS) and poststained with 0.2% (w/v) uranyl acetate and 4% (w/v) lead citrate. Images and tomograms were recorded using a Model 2040 dual-axis tomography holder (Fischione Instruments) on a Tecnai F20 200 kV field emission gun electron microscope (FEI) equipped with a DE20 camera (Direct Electron), or a Tecnai T12 120 kV field emission gun electron microscope (FEI) equipped with a 4kx4k Ultrascan 4000 CCD camera (Gatan). Dual-axis tilt series were acquired from − 60° to + 60° with an increment of 2° using SerialEM 35 and processed using IMOD 36 with nonlinear anisotropic diffusion filtering.
Proteomic analysis and pull-downs. Mature mock-or RAP-treated SERA6:loxP schizonts were incubated for ~4 h at 37 °C in complete medium supplemented with C2, then washed once in gassed, warm, protein-free medium containing C2 before rapidly washing twice in similar medium lacking C2, pelleting at 1,800 × g for 1 min. The cells were suspended at high density (~1 × 10 9 ml -1 ) in warm, proteinfree medium lacking C2 and incubated for just 20 min at 37 °C to allow progress to egress. The entire samples were then snap-frozen in liquid N 2 .
For global proteomic analysis, samples were thawed by the addition of an equal volume of ice-cold water containing protease inhibitors (cOmplete Protease Inhibitor Cocktail, Sigma-Aldrich), followed by centrifugation at 16,000 × g for 10 min at 4 °C to separate soluble and insoluble fractions. These were immediately fractionated by SDS-PAGE on NuPAGE 4-12% Bis-Tris gels (Invitrogen). Gels were stained with Quick Blue Coomassie (Triple Red) then the entire gel cut into 24 equally sized slices and proteins in excised slices subjected to tryptic digestion 37 . LC-MS/MS analysis was as described below.
For pull-down analysis, frozen schizont preparations were thawed in the presence of 1% (v/v) Nonidet P40 (CAS 68412-54-4, Santa Cruz Biotechnology), 10 mM EDTA and protease inhibitors (cOmplete Protease Inhibitor Cocktail, Sigma-Aldrich) and extracted at 4 °C for 1 h with intermittent vortexing. The extracts were clarified by centrifugation at 16,000 × g for 10 min at 4 °C, filtered through 0.22 μ m PVDF centrifugal filter units (MilliporeSigma), then incubated with ~2 μ g of the relevant anti-spectrin mAb for 1.5 h at 4 °C with gentle mixing. Precipitation of immune complexes with Protein G Sepharose 4 Fast Flow (GE Healthcare) followed the manufacturer's protocol. Bound complexes were subjected to SDS-PAGE and stained bands of interest excised and analysed by tryptic digestion and LC-MS/MS.
Mass spectrometry (LC-MS/MS).
Tryptic digests were chromatographically resolved using an Ultimate 3000 RSLCnano (Dionex) with an EASY-Spray column (2 μ m particle size, PepMap C18, 100 Å pore size, 50 cm × 75 μ m ID; Thermo Scientific). Spectra were acquired using an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) acquiring the top ten most intense ions in data dependent acquisition mode with collision-induced dissociation fragmentation at 35% normalized collision energy. For targeted work, data were acquired using an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scientific) using a mixture of data dependent fragmentation and three targeted fragmentations (545. Sample sizes varied across the study as follows: FACS analyses to determine parasitaemia counts routinely measured the numbers of parasite-infected cells in a total of 100,000 red blood cells. Since parasitaemia values ranged from 0.1-10%, this was considered sufficient to provide statistically robust measurements of parasitaemia. All genomic analyses (e.g. diagnostic PCR) used samples of DNA purified from at least 20 million parasites (estimated). All Western blot blot analyses used samples of extracts generated from at least 10 million parasites (estimated).
Other specific values (e.g. number of egress events used to determine egress efficiency) are provided in the figure legends and/or Methods.
Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful in all experiments. All experiments were repeated at least once (i.e. at least 2 biological replicates), and usually more often, as detailed for individual experiments in the paper (usually provided as an 'n' value).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Allocation of sample organisms was completely random. This study was entirely in vitro, using wild-type or transgenic microorganisms (Plasmodium falciparum).
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not relevant to most of this study since most assessments used entirely objective (e.g. numerical) read-outs. However, for examination of microscopic and gel-derived images blinding was not possible or was considered inappropriate.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials are readily available from the authors.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Three monoclonal antibodies specific for human beta-spectrin were used, all of which are commercially available from Santa Cruz Biotechnology. These were:
1. B-1 (cat #sc374309, clone #B-1, lot #A0912) 2. B-2 (cat #sc377437, clone #B-2, lot #J2212) 3. VD4 (cat #sc53901, clone #VD4, lot #E1607)
Validation statements for all 3 antibodies, including images of Western blots in which human cell extracts containing beta-spectrin are probed with the antibodies, are provided on the Santa Cruz website (https://www.scbt.com/scbt/home). Data provided in the manuscript also confirmed specific reactivity with human red blood cell beta-spectrin. A rabbit polyclonal antibody against mCherry (ab167453) was obtained from Abcam. Validation of its specificity is provided by the manufacturer on its website. Other primary antibodies were produced in our laboratory or other academic labs; relevant citations are provided in the paper.
